|1.||Davis, Paul J: 22 articles (06/2015 - 01/2008)|
|2.||Mousa, Shaker A: 18 articles (06/2015 - 01/2008)|
|3.||Lin, Hung-Yun: 16 articles (06/2015 - 11/2009)|
|4.||Davis, Faith B: 15 articles (06/2013 - 01/2008)|
|5.||Tang, Heng-Yuan: 9 articles (01/2015 - 11/2009)|
|6.||Luidens, Mary K: 6 articles (01/2013 - 11/2009)|
|7.||Glinsky, Gennadi V: 5 articles (06/2015 - 11/2009)|
|8.||Incerpi, Sandra: 5 articles (01/2015 - 09/2012)|
|9.||Hercbergs, Aleck: 5 articles (01/2015 - 08/2009)|
|10.||Meng, Ran: 5 articles (06/2013 - 01/2011)|
12/10/2012 - "These results suggest the potential of tetrac as a new ligand moiety for enhancing the delivery of anticancer drug-loaded nanoparticles to tumors and enhancing the therapeutic efficacy of encapsulated anticancer drugs."
06/20/2015 - "In a nanoparticulate formulation limiting its action to αvβ3, tetrac modulates integrin-dependent effects on gene expression in human cancer cell lines that include increased expression of a panel of pro-apoptotic genes and decreased transcription of defensive anti-apoptotic XIAP and MCL1 genes. "
06/01/2014 - "Negative correlations were found between TW and AP activity in tumors from control hyper- and hypothyroid groups and an inverse relationship was observed between TW and AP activities in tetrac-treated mice. "
01/01/2014 - "This reformulation has greater potency than unmodified tetrac at the integrin and affects a broader range of cancer-relevant genes. "
01/01/2014 - "Tetrac blocks the transcriptional activities directed by T4 and T3 at αvβ3, but, independently of T4 and T3, tetrac modulates transcription of cancer cell genes that are important to cell survival pathways, control of the cell cycle, angiogenesis, apoptosis, cell export of chemotherapeutic agents, and repair of double-strand DNA breaks. "
|2.||Breast Neoplasms (Breast Cancer)
01/01/2008 - "In vivo studies reported here revealed that tetrac in a pulsed-dose regimen was effective in suppressing the growth of a doxorubicin-resistant human breast tumor in the nude mouse. "
12/01/2013 - "Tetraiodothyroacetic acid-conjugated PLGA nanoparticles: a nanomedicine approach to treat drug-resistant breast cancer."
11/01/2009 - "Expression of apoptosis inhibitors XIAP (X-linked inhibitor of apoptosis) and MCL1 (myeloid cell leukemia sequence 1) was downregulated by nanoparticulate tetrac in these breast cancer cells whereas apoptosis-promoting CASP2 and BCL2L14 were upregulated by the nanoparticulate formulation. "
11/01/2009 - "Here we describe actions initiated at the cell surface receptor by unmodified tetrac and nanoparticulate tetrac on a panel of survival pathway genes in estrogen receptor-negative human breast cancer (MDA-MB-231) cells. "
11/01/2009 - "MDA-MB-231 cells are estrogen receptor-negative human breast cancer cells shown to be responsive to tetrac in terms of decreased cell proliferation. "
|3.||Squamous Cell Neoplasms (Squamous Cell Cancer)
|4.||Thyroid Neoplasms (Thyroid Cancer)
|5.||Lung Neoplasms (Lung Cancer)
01/01/2011 - "Activity as an inhibitor of lung cancer cell proliferation induced at the integrin receptor makes tetrac a novel anti-proliferative agent."
01/01/2011 - "Tetraiodothyroacetic acid (tetrac) lacks thyroid hormone function but inhibits binding of T(4) and T(3) to the integrin receptor; tetrac eliminated thyroid hormone-induced lung cancer cell proliferation and ERK1/2 activation. "
|1.||tetraiodothyroacetic acid (TA(4))
|4.||squamous cell carcinoma-related antigen
|1.||Heterologous Transplantation (Xenotransplantation)
|3.||Islets of Langerhans Transplantation